High Impact Technology Fund selects Blue River Bio's program
The High Impact Technology (HIT) Fund selected Blue River Bio's program for a competitive award that pairs teams with executive advisors and industry connections to de-risk commercialization.
Blue River Bio’s program was selected for the High Impact Technology (HIT) Fund, a competitive award program run by the Stanford Office of Technology Licensing.
The HIT Fund provides strategic and advisory support to help promising technologies become new products and companies. Awardees are matched with experienced industry executive advisors and introduced to strategic partners and investors, with the aim of de-risking the path to commercialization.
For Blue River Bio, the program’s advisors helped shape our clinical trial design and commercialization strategy through engagement with physicians, payers, and regulatory experts.
